Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Palantir Technologies raises its full-year outlook but the stock falls, Ford suspends guidance because of uncertainty over ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 66.67% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including ...

Palantir Technologies shares are down nearly 8% after the software group's stellar earnings could not prevent some profit taking after the stock's strong rally to near record highs.